CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.76BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9190xvs all stocks
52-Week Change
68.93%vs all stocks
Market Capitalization
2.76BUSDvs all stocks (USD)
Enterprise Value
2.24BUSDvs all stocks (USD)
Forward P/E
-9.98xvs Biotechnology peers
Price to Book (MRQ)
5.53xvs Biotechnology peers
Enterprise to EBITDA
-5.86xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-38.90%vs Biotechnology peers
Return on Equity (TTM)
-71.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-382.89MUSDvs all stocks (USD)
Net Income (TTM)
-368.95MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-293.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-179.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-315.47MUSDvs all stocks (USD)
Pre-tax Income
-299.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.00KUSDFY2025 · Dec 31, 2025Net Income
-299.62MUSDFY2025 · Dec 31, 2025EBIT
-292.08MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-291.62MUSDFY2025 · Dec 31, 2025Research & Development
215.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
100.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
24.48MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.53MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-299.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-244.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-245.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
354.73MUSDFY2025 · Dec 31, 2025Interest Paid
6.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-299.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
468.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.93MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.11MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
13.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.43MUSDFY2025 · Dec 31, 2025Capital Expenditures
-630.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-310.45MUSDFY2025 · Dec 31, 2025Sale of Investments
506.16MUSDFY2025 · Dec 31, 2025Other Investing Activity
-800.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
194.29MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
23.34MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-21.92MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
301.92MUSDFY2025 · Dec 31, 2025Shares Outstanding
71.73MSharesUpdated Jul 19, 2026Float Shares
51.95MSharesUpdated Jul 19, 2026Shares Short
13.52MSharesUpdated Jul 19, 2026Short Ratio
7.83daysvs all stocks
Short % of Shares Outstanding
21.45%vs all stocks
% Held by Insiders
0.78%vs all stocks
% Held by Institutions
110.69%vs all stocks
Total Cash (MRQ)
596.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.31USDUpdated Jul 19, 2026Total Debt (MRQ)
76.89MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1539xvs Biotechnology peers
Current Ratio (MRQ)
13.64xvs Biotechnology peers
Book Value per Share (MRQ)
6.97USDUpdated Jul 19, 2026Total Assets
734.73MUSDvs all stocks (USD)
Total Current Assets
728.88MUSDFY2025 · Dec 31, 2025Total Liabilities
130.21MUSDFY2025 · Dec 31, 2025Total Non-current Assets
5.85MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
76.76MUSDFY2025 · Dec 31, 2025Total Current Liabilities
53.45MUSDFY2025 · Dec 31, 2025Cash
4.62MUSDFY2025 · Dec 31, 2025Cash Equivalents
350.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
354.73MUSDFY2025 · Dec 31, 2025Other Short-term Investments
359.86MUSDFY2025 · Dec 31, 2025Accounts Payable
21.90MUSDFY2025 · Dec 31, 2025Short-term Debt
549.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.37MUSDFY2025 · Dec 31, 2025Long-term Debt
76.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
71.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-760.87MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
604.52MUSDvs all stocks (USD)
52-Week Low
19.07USDUpdated Jul 19, 202652-Week High
56.05USDUpdated Jul 19, 202652-Week Change
68.93%vs all stocks
Beta
0.9190xvs all stocks
50-Day MA
37.11USDUpdated Jul 19, 2026200-Day MA
38.70USDUpdated Jul 19, 2026Avg 10-Day Volume
2.76MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.22MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-5.54USDUpdated Jul 19, 2026Other Income / Expense
-1.09MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Altman Z-Score 11.08: safe zoneNotable
Altman Z-Score: 11.08
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.76B, above the global median of $1.15BNotable
Market cap (USD): 2,763,641,804Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule